Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trialJohn M. Kirkwood, Georgina V. Long, Jean‐Jacques Grob et al.|Nature Medicine|2023Cited by 208
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgeryJohn M. Kirkwood, Georgina V. Long, Michele Del Vecchio et al.|Future Oncology|2024Cited by 2